Scarica l'app Stockscreener
239.83
0.18%
0.43
Pre-mercato:
239.11
-0.72
-0.30%
Precedente Chiudi:
$239.40
Aprire:
$242.93
Volume 24 ore:
549.78K
Relative Volume:
0.55
Capitalizzazione di mercato:
$15.05B
Reddito:
$4.44B
Utile/perdita netta:
$29.49M
Rapporto P/E:
-13,034.24
EPS:
-0.0184
Flusso di cassa netto:
$1.19B
1 W Prestazione:
+4.83%
1M Prestazione:
+18.49%
6M Prestazione:
+35.55%
1 anno Prestazione:
+122.45%
Intervallo 1D:
$239.20
$243.32
Intervallo di 1 settimana:
$227.64
$243.32
Portata 52W:
$105.00
$243.32
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
239.83 | 15.02B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Narcolepsy Market Trends, Innovation, and Future Growth Outlook to 2034 – DelveInsight | Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and Promising Pipeline Propel Growth Potential - DirectorsTalk Interviews
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
Banking giant massively resets Jazz Pharma stock price target - AOL.com
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Momentum - Yahoo Finance
JAZZ Maintained by Piper Sandler -- Price Target Raised to $301 - GuruFocus
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
Proposed sale: JAZZ (NASDAQ) 2,000 shares listed for $482,000 on 05/22/2026 - Stock Titan
JAZZ Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
Piper Sandler raises Jazz Pharmaceuticals stock price target on zanidatamab outlook By Investing.com - Investing.com South Africa
Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ) - Insider Monkey
Bernstein initiates coverage of Jazz Pharmaceuticals (JAZZ) with market perform recommendation - MSN
UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point - AOL.com
Jazz Pharmaceuticals (JAZZ) Coverage Initiated with Caution by B - GuruFocus
How Investors Are Reacting To Jazz Pharmaceuticals (JAZZ) Reaffirmed Guidance And Rare-Disease Portfolio Momentum - simplywall.st
Jazz Pharma raised to Buy at UBS on Ziihera potential - MSN
Jazz Pharmaceuticals stock hits all-time high at $241.00 By Investing.com - Investing.com Australia
Jazz Pharmaceuticals stock hits all-time high at $241.00 - Investing.com India
10 Best European Growth Stocks to Buy - Insider Monkey
JAZZ Upgraded by UBS -- Price Target Raised to $307 - GuruFocus
Jazz Pharmaceuticals (JAZZ) Upgraded to Buy by UBS with Target P - GuruFocus
UBS upgrades Jazz Pharmaceuticals stock rating on Ziihera potential By Investing.com - Investing.com Nigeria
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More - Yahoo Finance
Jazz Pharmaceuticals PLC at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
JAZZ Technical Analysis | Trend, Signals & Chart Patterns | JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) - ChartMill
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings Signal Promising Growth Potential - DirectorsTalk Interviews
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Strong Q1 Earnings And Upcoming FDA And Study Catalysts - simplywall.st
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Swedbank AB Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations - MSN
Truist Financial Corp Has $1.86 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Jazz Pharmaceuticals stock hits all-time high at $230.85 By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals stock hits all-time high at $230.85 - Investing.com
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock? - TradingView
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings - simplywall.st
Some Investors May Be Willing To Look Past Jazz Pharmaceuticals' (NASDAQ:JAZZ) Soft Earnings - Yahoo Finance
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Here’s What Analysts Are Saying About Jazz Pharmaceuticals (JAZZ) Post Q1 Results - Insider Monkey
Three Jazz Pharmaceuticals investor webcasts set for May–June 2026 - Stock Titan
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):